ArticleEuropean journal of nuclear medicine and molecular imaging2017
The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma.
Article in European journal of nuclear medicine and molecular imaging, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review.Radiation oncology (London, England) · 2022Pooled it
- Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.The Cochrane database of systematic reviews · 2021Pooled it
- Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.Journal of neuro-oncology · 2020Pooled it
- Feasibility of multi-parametric PET and MRI for prediction of tumour recurrence in patients with glioblastoma.European journal of nuclear medicine and molecular imaging · 2019Trial
- Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation.PloS one · 2019Trial
- Diagnostic and Prognostic Value of Hypoxia PET in Glioma: A Systematic Review and Meta-Analysis.Cancers · 2026Review
- Imaging Biomarkers in Radiotherapy.Cancers · 2026Review
- Metabolic Heterogeneity in High-Grade Glioma Assessed by Multi-Tracer PET and Ex Vivo Metabolomics: A Systematic Review and Meta-Analysis.Metabolites · 2025Review
- Deep Learning Segmentation of Infiltrative and Enhancing Cellular Tumor at Pre- and Posttreatment Multishell Diffusion MRI of Glioblastoma.Radiology. Artificial intelligence · 2024Article
- A prospective clinical study of the influence of oral protein intake on [EJNMMI research · 2024Article
- A PET probe targeting polyamine transport system for precise tumor diagnosis and therapy.Asian journal of pharmaceutical sciences · 2024Article
- Diagnostic and theranostic opportunities in Neuro-oncology.Advances in oncology · 2024Article
- Integrating multi-modal imaging in radiation treatments for glioblastoma.Neuro-oncology · 2024Review
- Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06.European journal of nuclear medicine and molecular imaging · 2023Article
- [BMJ open · 2023Article
- Combining amino acid PET and MRI imaging increases accuracy to define malignant areas in adult glioma.Nature communications · 2023Article
- Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma.Pharmaceutics · 2023Review
- Therapy Defining at Initial Diagnosis of Primary Brain Tumor-The Role ofBiomedicines · 2023Article
- Combination of pre-treatment dynamic [European journal of nuclear medicine and molecular imaging · 2023Article
- DeepDixon synthetic CT for [Frontiers in neuroscience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma patients show a great variability in progression free survival (PFS) and overall survival (OS). To gain additional pretherapeutic information, we explored the potential of O-(2-
methodsWe retrospectively analyzed 146 consecutively treated, newly diagnosed glioblastoma patients. All patients were treated with temozolomide and radiation therapy (RT). CT/MR and FET PET scans were obtained postoperatively for RT planning. We used Cox proportional hazards models with OS and PFS as endpoints, to test the prognostic value of FET PET biological tumor volume (BTV).
resultsMedian follow-up time was 14 months, and median OS and PFS were 16.5 and 6.5 months, respectively. In the multivariate analysis, increasing BTV (HR = 1.17, P < 0.001), poor performance status (HR = 2.35, P < 0.001), O(6)-methylguanine-DNA methyltransferase protein status (HR = 1.61, P = 0.024) and higher age (HR = 1.32, P = 0.013) were independent prognostic factors of poor OS. For poor PFS, only increasing BTV (HR = 1.18; P = 0.002) was prognostic. A prognostic index for OS was created based on the identified prognostic factors.
conclusionLarge BTV on FET PET is an independent prognostic factor of poor OS and PFS in glioblastoma patients. With the introduction of FET PET, we obtain a prognostic index that can help in glioblastoma treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.